Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EGVG | ISIN: US49457M1062 | Ticker-Symbol:
NASDAQ
21.11.24
15:36 Uhr
0,941 US-Dollar
+0,041
+4,56 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
KINDLY MD INC Chart 1 Jahr
5-Tage-Chart
KINDLY MD INC 5-Tage-Chart
ACCESSWIRE
370 Leser
Artikel bewerten:
(2)

KindlyMD, Inc: KindlyMD Announces Second Quarter 2024 Financial Results and Provides Shareholder Update

Finanznachrichten News

Company provides nearly 80% statewide comprehensive insurance coverage in Utah under contract with providers such as Medicare, Select Health, Medicaid, and Blue Cross Blue Shield

Reimbursement from insurance payors increased 163.7% sequentially and is expected to increase as a percentage of total revenue going forward

Reimbursements from insurance payors totaled $126,325 in first half of 2024 as compared to $0 during the first half of 2023

SALT LAKE CITY, UT / ACCESSWIRE / August 14, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, today announced its financial results for the second quarter ended June 30, 2024 and is providing a shareholder update.

Tim Pickett, PA-C, KindlyMD Founder and CEO, stated, "During the second quarter we successfully closed on our IPO for gross proceeds of approximately $6 million. While from a total revenue perspective during the quarter we did not yet yield the return on investment from the additional working capital we received, we are very pleased with the 163.7% sequential growth in reimbursement from insurance payors. As Utah's first alternative medical treatment company to contract under the state's top insurance payors, we are laser focused on growing this segment of our revenue stream. We are now proud to provide nearly 80% of statewide comprehensive insurance coverage to the Utah community, through top providers including Medicare, Select Health, Medicaid, and Blue Cross Blue Shield, according to the 2023 Utah Health Insurance Market Report. We are working to continue this growth trend, particularly as we invest in the acquisition of new patients to our facilities."

"Our team is also focused on aggressive growth via accretive acquisitions of clinics in Utah to expand our footprint. As a leader in the market, we see significant opportunity to potentially acquire profitable locations and integrate onto our platform driving operational synergies and margin expansion. The market is highly fragmented, and our potential pipeline remains robust. We look forward to updating our shareholders on our progress in the near future."

Operational Highlights:

  • Completed IPO in June 2024 for net proceeds of $6.02 million

  • Achieved nearly 80% statewide comprehensive insurance coverage in Utah according to the 2023 Utah Health Insurance Market Report

  • Became Utah's first alternative medical treatment company to contract under the state's top insurance payors, which now include Medicare, Select Health and Medicaid and Blue Cross Blue Shield

  • Collaborated with Curaleaf to expand patient education on medical cannabis care in Utah with community care events held at multiple Curaleaf Utah medical cannabis pharmacies

  • Successfully registered on SAM.gov, the official U.S. federal funding platform

Subsequent Events:

  • Submitted a comment to the U.S. Department of Justice, following its recent proposed rule to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act

Financial Highlights for the Quarterly Period Ended June 30, 2024

The Company earned $91,553 in reimbursements from insurance payors during the three months ending June 30, 2024, an increase of 163.7% over the $34,722 earned for the three months ending March 31, 2024. The Company earned $126,325 in reimbursements from insurance payors during the six months ended June 30, 2024, as compared to $0 during the three and six months ended June 30, 2023.

Revenues decreased by $340,481, or 34.8%, to $639,057 for the three months ended June 30, 2024, from $979,538 for the three months ended June 30, 2023. The decrease in revenues is primarily attributed to a decrease in cash-pay patient care services as KindlyMD continues to shift toward insurance billing with commercial and governmental payers including Medicare, Medicaid, Select Health, Blue Cross Blue Shield, and other commercial payers compared to the prior period.

Operating expenses increased by $95,423, or 6.0%, to $1,676,250 for the three months ended June 30, 2024, from $1,580,827 for the three months ended June 30, 2023. The increase in operating expenses is primarily attributable to an increase in general and administrative expenses, salaries and wages, and cost of revenues.

Net loss per share decreased by $0.13, or 100.0%, to $(0.26) for the three months ended June 30, 2024, compared to $(0.13) for the three months ended June 30, 2023. KindlyMD management strives to look for opportunities to optimize revenue by increasing sales, acquiring additional clinics, improving margins, and controlling ongoing operating expenses.

As of June 30, 2024, the Company had cash and cash equivalents of $4.74 million and total working capital of $4.11 million.

In June 2024, KindlyMD completed its IPO for total net proceeds of $6.02 million, providing adequate liquidity and cash reserves to meet its obligations for at least the 12-month period following June 30, 2024, and to assist the Company in implementing its strategic operational business plans to create sustained cash flow generation thereafter.

As of August 9, 2024, the Company had 5,947,169 common shares outstanding.

About KindlyMD

KindlyMD? is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers, including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.

For more information, please visit www.kindlymd.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in KindlyMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. KindlyMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

Investor Relations Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
KindlyMD@KCSA.com

KINDLY MD, INC.
CONDENSED BALANCE SHEETS

June 30, 2024

December 31, 2023

(Unaudited)

ASSETS

Current Assets

Cash and cash equivalents

$

4,740,006

$

525,500

Accounts receivable

5,182

28,001

Inventories, net

3,825

63,202

Prepaid expenses and other current assets

305,655

225

Total Current Assets

5,054,668

616,928

Property and equipment, net

206,816

235,292

Operating lease right-of-use assets

184,177

235,706

Security deposits

11,276

11,276

TOTAL ASSETS

$

5,456,937

$

1,099,202

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities

Accounts payable and accrued expenses

$

628,749

$

329,810

Customer deposits

4,150

3,425

Current portion of operating lease liabilities

79,973

94,696

Current portion of finance lease liabilities

2,010

-

Current portion of notes payable, net

228,061

148,517

Derivative liability

-

238,000

Total Current Liabilities

942,943

814,448

Operating lease liabilities, net of current portion

124,651

164,295

Finance lease liabilities, net of current portion

8,635

Notes payable, net of current portion

-

228,871

TOTAL LIABILITIES

1,076,229

1,207,614

Stockholders' Equity (Deficit)

Preferred Stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding as of June 30, 2024 and December 31, 2023

-

-

Common stock, $0.001 par value, 100,000,000 shares authorized; 5,939,516 and 4,617,798 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively

5,940

4,618

Additional paid-in capital

10,134,801

4,045,024

Accumulated deficit

(5,760,033

)

(4,158,054

)

TOTAL STOCKHOLDERS' EQUITY (DEFICIT)

4,380,708

(108,412

)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

$

5,456,937

$

1,099,202

KINDLY MD, INC.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)

For the Three Months Ended
June 30,

For the Six Months Ended
June 30,

2024

2023

2024

2023

Revenues

$

639,057

$

979,538

$

1,468,086

$

2,139,883

Operating Expenses

Cost of revenues

61,947

59,508

69,691

108,132

Salaries and wages

1,126,893

1,109,559

1,834,859

2,042,860

General and administrative

461,677

385,536

787,222

743,719

Depreciation

25,733

26,224

50,634

51,666

Total Operating Expenses

1,676,250

1,580,827

2,742,406

2,946,377

LOSS FROM OPERATIONS

(1,037,193

)

(601,289

)

(1,274,320

)

(806,494

)

Other Income (Expenses)

Other income

13,828

13,075

25,868

37,301

Interest expense

(318,450

)

(8,194

)

(375,689

)

(8,194

)

Loss on extinguishment of debt

(38,889

)

(38,889

)

Gain on change in fair value of derivative liability

61,051

-

61,051

-

Total Other Income (Expenses)

(282,460

)

4,881

(327,659

)

29,107

NET LOSS BEFORE INCOME TAXES

(1,319,653

)

(596,408

)

(1,601,979

)

(777,387

)

INCOME TAX EXPENSE

-

-

-

-

NET LOSS

$

(1,319,653

)

$

(596,408

)

$

(1,601,979

)

$

(777,387

)

LOSS PER COMMON SHARE - BASIC AND DILUTED

$

(0.26

)

$

(0.13

)

$

(0.33

)

$

(0.17

)

WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED

5,009,956

4,455,912

4,813,877

4,445,714

KINDLY MD, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)

For the Six Months Ended
June 30,

2024

2023

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss

$

(1,601,979

)

$

(777,387

)

Adjustments to reconcile loss to net cash used in operating activities:

Stock-based compensation

15,500

338,021

Depreciation expense

50,634

51,666

Loss on extinguishment of debt

38,889

-

Gain on change in fair value of derivative liability

(61,051

)

-

Amortization of debt discounts

357,439

876

Amortization of right-of-use assets

51,529

61,589

Changes in operating assets and liabilities:

Accounts receivable

22,819

4,161

Inventories

59,377

(9,822

)

Prepaid expenses and other current assets

(305,430

)

11,039

Security deposits

-

731

Accounts payable and accrued expenses

298,939

106,668

Customer deposits

725

300

Operating lease liabilities

(54,367

)

(62,806

)

Net cash used in operating activities

(1,126,976

)

(274,964

)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases of property and equipment

(11,182

)

(14,420

)

Net cash used in investing activities

(11,182

)

(14,420

)

CASH FLOWS FROM FINANCING ACTIVITIES

Net proceeds from issuance of notes payable

45,000

-

Net proceeds from issuance of related party note payable

233,373

Net proceeds from issuance of common shares and warrants in connection with a public offering

5,860,650

-

Repayments of related party note payable

-

(20,282

)

Repayments of notes payable

(552,655

)

-

Repayments of finance lease liabilities

(331

)

-

Net cash provided by financing activities

5,352,664

213,091

NET CHANGE IN CASH AND CASH EQUIVALENTS

4,214,506

(76,293

)

CASH AND CASH EQUIVALENTS

Beginning of the period

525,500

186,918

End of the period

$

4,740,006

$

110,625

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

Cash paid for interest

$

19,089

$

-

Cash paid for income taxes

$

-

$

-

NON-CASH INVESTING AND FINANCING ACTIVITIES

Debt discounts on notes payable

$

10,556

$

-

Debt discount on related party note payable

$

-

$

16,627

Fair value of derivative liability recognized upon issuance of notes payable

$

38,000

$

-

Extinguishment of derivative liability upon settlement of notes payable

$

214,949

$

-

Finance purchases of property and equipment

$

10,976

$

-

SOURCE: KindlyMD, Inc



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.